Paul M. Schneider

12.7k total citations · 2 hit papers
198 papers, 9.0k citations indexed

About

Paul M. Schneider is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Paul M. Schneider has authored 198 papers receiving a total of 9.0k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Pulmonary and Respiratory Medicine, 87 papers in Surgery and 57 papers in Molecular Biology. Recurrent topics in Paul M. Schneider's work include Esophageal Cancer Research and Treatment (71 papers), Gastric Cancer Management and Outcomes (58 papers) and Lung Cancer Treatments and Mutations (23 papers). Paul M. Schneider is often cited by papers focused on Esophageal Cancer Research and Treatment (71 papers), Gastric Cancer Management and Outcomes (58 papers) and Lung Cancer Treatments and Mutations (23 papers). Paul M. Schneider collaborates with scholars based in Germany, Switzerland and United States. Paul M. Schneider's co-authors include Ralf Metzger, Stephan Baldus, Elfriede Bollschweiler, Arnulf H. Hölscher, Jan Brabender, Wolfgang E. Berdel, Carsten Müller‐Tidow, Hubert Serve, Sven Diederichs and Michael Thomas and has published in prestigious journals such as Advanced Materials, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Paul M. Schneider

195 papers receiving 8.8k citations

Hit Papers

2 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer

2003 1.8k citations Ping Ji, Sven Diederichs et al. profile →
Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954

2010 507 citations Arnulf H. Hoelscher, Paul M. Schneider et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul M. Schneider Germany	45	3.7k	3.4k	3.0k	2.3k	1.9k	198	9.0k
Ralf Metzger Germany	40	3.7k 1.0×	2.6k 0.8×	2.5k 0.8×	2.5k 1.1×	2.9k 1.5×	131	8.2k
Masato Kusunoki Japan	51	3.4k 0.9×	2.4k 0.7×	3.6k 1.2×	2.6k 1.1×	4.2k 2.2×	492	11.1k
Wilfried Budach Germany	51	1.8k 0.5×	4.5k 1.3×	3.6k 1.2×	1.8k 0.8×	2.7k 1.4×	334	10.4k
Shoji Natsugoe Japan	43	1.7k 0.5×	3.2k 0.9×	2.8k 0.9×	1.3k 0.6×	2.9k 1.5×	307	7.4k
Kiyokazu Nakajima Japan	48	1.8k 0.5×	3.4k 1.0×	3.9k 1.3×	982 0.4×	1.8k 0.9×	407	7.8k
Kazuo Shirouzu Japan	49	2.0k 0.5×	2.9k 0.8×	3.8k 1.3×	786 0.3×	4.2k 2.2×	484	8.8k
Mark Bloomston United States	43	2.2k 0.6×	1.6k 0.5×	2.6k 0.9×	2.1k 0.9×	3.4k 1.7×	159	7.5k
Arnulf H. Hölscher Germany	44	1.6k 0.4×	3.7k 1.1×	3.9k 1.3×	583 0.3×	1.6k 0.8×	241	7.0k
Tetsuo Ohta Japan	46	1.9k 0.5×	1.9k 0.6×	3.0k 1.0×	1.1k 0.5×	3.7k 1.9×	338	7.3k
Christopher W. Ryan United States	38	1.5k 0.4×	3.7k 1.1×	1.1k 0.4×	975 0.4×	1.9k 1.0×	165	5.9k

Countries citing papers authored by Paul M. Schneider

Since Specialization

Citations

This map shows the geographic impact of Paul M. Schneider's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul M. Schneider with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul M. Schneider more than expected).

Fields of papers citing papers by Paul M. Schneider

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul M. Schneider. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul M. Schneider. The network helps show where Paul M. Schneider may publish in the future.

Co-authorship network of co-authors of Paul M. Schneider

This figure shows the co-authorship network connecting the top 25 collaborators of Paul M. Schneider. A scholar is included among the top collaborators of Paul M. Schneider based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul M. Schneider. Paul M. Schneider is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fichter, Michael, Alexander Fuchs, Paul M. Schneider, et al.. (2025). Unfolding and Degradation of Micellar Immunodrug Carriers Derived From End Group Modified Aliphatic Poly(Carbonate)s with Acid‐Responsive Ketal Side Groups. Advanced Materials. 38(8). e11752–e11752.

Schneider, Paul M., et al.. (2024). Co-delivery of STING and TLR7/8 agonists in antigen-based nanocapsules to dendritic cells enhances CD8+ T cell-mediated melanoma remission. Nano Today. 57. 102365–102365. 3 indexed citations

Jung, Carina, Michael Fichter, Paul M. Schneider, et al.. (2024). Nanobodies Outperform Antibodies – Rapid Functionalization with Equal In Vivo Targeting Properties. Advanced Materials. 36(52). e2412563–e2412563. 5 indexed citations

Schneider, Paul M., Hua Zhang, Ömer Öztürk, et al.. (2023). In vivo gene silencing with novel siRNA loaded polypeptoide nanoparticles for anti-stromal therapy in hepatocellular carcinoma. Zeitschrift für Gastroenterologie. 61(8). e492–e493. 1 indexed citations

Kaps, Leonard, Paul M. Schneider, Maximiliano L. Cacicedo, et al.. (2023). Liver Cell Type-Specific Targeting by Nanoformulations for Therapeutic Applications. International Journal of Molecular Sciences. 24(14). 11869–11869. 7 indexed citations

Kaps, Leonard, Paul M. Schneider, Ion Andronache, et al.. (2023). A New Synthetic Curcuminoid Displays Antitumor Activities in Metastasized Melanoma. Cells. 12(22). 2619–2619. 7 indexed citations

Jakubczyk, Michał, et al.. (2023). This Dead or That Dead: Framing Effects in the Evaluation of Health States. Value in Health. 27(1). 95–103. 7 indexed citations

Ruellas, Antônio Carlos de Oliveira, Lucía Cevidanes, Tung Nguyen, et al.. (2020). Three-dimensional condylar changes from Herbst appliance and multibracket treatment: A comparison with matched Class II elastics. American Journal of Orthodontics and Dentofacial Orthopedics. 158(4). 505–517.e6. 17 indexed citations

Heggie, Andrew A., et al.. (2016). Skeletal stability of maxillary advancement with and without a mandibular reduction in the cleft lip and palate patient. International Journal of Oral and Maxillofacial Surgery. 45(12). 1501–1507. 16 indexed citations

10.

Fischer, Michael A., Daniel Nanz, Thomas F. Hany, et al.. (2010). Diagnostic accuracy of whole-body MRI/DWI image fusion for detection of malignant tumours: a comparison with PET/CT. European Radiology. 21(2). 246–255. 44 indexed citations

11.

Prenzel, Klaus, Ute Warnecke‐Eberz, Jan Brabender, et al.. (2006). Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater. World Journal of Gastroenterology. 12(3). 437–437. 8 indexed citations

12.

Sarbia, Mario, Helene Geddert, Wolfgang A. Schulz, et al.. (2005). Methylenetetrahydrofolate reductaseC677T polymorphism and risk of adenocarcinoma of the upper gastrointestinal tract. Scandinavian Journal of Gastroenterology. 40(1). 109–111. 17 indexed citations

13.

Miyazono, Futoshi, Ralf Metzger, Ute Warnecke‐Eberz, et al.. (2004). Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. British Journal of Cancer. 91(4). 666–672. 39 indexed citations

14.

Diederichs, Sven, Etmar Bulk, Björn Steffen, et al.. (2004). S100 Family Members and Trypsinogens Are Predictors of Distant Metastasis and Survival in Early-Stage Non-Small Cell Lung Cancer. Cancer Research. 64(16). 5564–5569. 168 indexed citations

15.

Mende, Ylva, Paul M. Schneider, Stephan Baldus, & Walter Doerfler. (2004). PCR-screening of human esophageal and bronchial cancers reveals absence of adenoviral DNA sequences. Virus Research. 104(1). 81–85. 6 indexed citations

16.

Bollschweiler, E., Paul M. Schneider, Stefan Mönig, et al.. (2003). Prognoserelevanz von biologischen und molekularen Markern in der Onkologie. Der Chirurg. 74(2). 139–144. 3 indexed citations

17.

Prenzel, Klaus, Stefan Mönig, Jan Malte Sinning, et al.. (2003). Role of skip metastasis to mediastinal lymph nodes in non‐small cell lung cancer. Journal of Surgical Oncology. 82(4). 256–260. 76 indexed citations

18.

Schneider, Paul M., Oliver Stoeltzing, John T. Manning, et al.. (2000). Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. British Journal of Cancer. 83(4). 473–479. 71 indexed citations

19.

Schneider, Paul M., Alan G. Casson, Bernard Levin, et al.. (1996). Mutations of p53 in barrett's esophagus and barrett's cancer: A prospective study of ninety-eight cases. Journal of Thoracic and Cardiovascular Surgery. 111(2). 323–333. 92 indexed citations

20.

Schneider, Paul M., F Lutz, & H.R. Mühlemann. (1979). Clinical evaluation of porous alumina ceramic dental implants.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 8(3). 371–9. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact